Infectious complications of pentostatin therapy.

Julie Marie Vose, F. Cabanillas, S. O'Brien, N. Dang, R. Drapkin, F. Foss

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Managing the infectious complications associated with pentostatin (Nipent), used alone or in combination with other agents in patients with low-grade lymphomas, poses a significant problem for clinicians. Since there is limited experience with these therapies, definitive treatment recommendations concerning prophylaxis cannot be made. The panel members discussed the use of valacyclovir (Valtrex) to provide prophylaxis for herpes zoster, trimethoprim/sulfamethoxazole for Pneumocystis, and acyclovir (Zovirax) for varicella zoster. They also considered combinations of pentostatin with agents such as interferon, rituximab (Rituxan), and chlorambucil (Leukeran) and their effect on the immune system. The biology of B and T cells was discussed, with an emphasis on clinical application.

Original languageEnglish (US)
Pages (from-to)41-42
Number of pages2
JournalOncology (Williston Park, N.Y.)
Volume14
Issue number6 Suppl 2
StatePublished - Jan 1 2000

Fingerprint

valacyclovir
Pentostatin
Chlorambucil
Acyclovir
Herpes Zoster
Pneumocystis
Chickenpox
Sulfamethoxazole Drug Combination Trimethoprim
Proxy
Non-Hodgkin's Lymphoma
Interferons
Immune System
B-Lymphocytes
Therapeutics
T-Lymphocytes
Rituximab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Vose, J. M., Cabanillas, F., O'Brien, S., Dang, N., Drapkin, R., & Foss, F. (2000). Infectious complications of pentostatin therapy. Oncology (Williston Park, N.Y.), 14(6 Suppl 2), 41-42.

Infectious complications of pentostatin therapy. / Vose, Julie Marie; Cabanillas, F.; O'Brien, S.; Dang, N.; Drapkin, R.; Foss, F.

In: Oncology (Williston Park, N.Y.), Vol. 14, No. 6 Suppl 2, 01.01.2000, p. 41-42.

Research output: Contribution to journalArticle

Vose, JM, Cabanillas, F, O'Brien, S, Dang, N, Drapkin, R & Foss, F 2000, 'Infectious complications of pentostatin therapy.', Oncology (Williston Park, N.Y.), vol. 14, no. 6 Suppl 2, pp. 41-42.
Vose JM, Cabanillas F, O'Brien S, Dang N, Drapkin R, Foss F. Infectious complications of pentostatin therapy. Oncology (Williston Park, N.Y.). 2000 Jan 1;14(6 Suppl 2):41-42.
Vose, Julie Marie ; Cabanillas, F. ; O'Brien, S. ; Dang, N. ; Drapkin, R. ; Foss, F. / Infectious complications of pentostatin therapy. In: Oncology (Williston Park, N.Y.). 2000 ; Vol. 14, No. 6 Suppl 2. pp. 41-42.
@article{804d39346a3a4645aa0b7c59040fae4f,
title = "Infectious complications of pentostatin therapy.",
abstract = "Managing the infectious complications associated with pentostatin (Nipent), used alone or in combination with other agents in patients with low-grade lymphomas, poses a significant problem for clinicians. Since there is limited experience with these therapies, definitive treatment recommendations concerning prophylaxis cannot be made. The panel members discussed the use of valacyclovir (Valtrex) to provide prophylaxis for herpes zoster, trimethoprim/sulfamethoxazole for Pneumocystis, and acyclovir (Zovirax) for varicella zoster. They also considered combinations of pentostatin with agents such as interferon, rituximab (Rituxan), and chlorambucil (Leukeran) and their effect on the immune system. The biology of B and T cells was discussed, with an emphasis on clinical application.",
author = "Vose, {Julie Marie} and F. Cabanillas and S. O'Brien and N. Dang and R. Drapkin and F. Foss",
year = "2000",
month = "1",
day = "1",
language = "English (US)",
volume = "14",
pages = "41--42",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "6 Suppl 2",

}

TY - JOUR

T1 - Infectious complications of pentostatin therapy.

AU - Vose, Julie Marie

AU - Cabanillas, F.

AU - O'Brien, S.

AU - Dang, N.

AU - Drapkin, R.

AU - Foss, F.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Managing the infectious complications associated with pentostatin (Nipent), used alone or in combination with other agents in patients with low-grade lymphomas, poses a significant problem for clinicians. Since there is limited experience with these therapies, definitive treatment recommendations concerning prophylaxis cannot be made. The panel members discussed the use of valacyclovir (Valtrex) to provide prophylaxis for herpes zoster, trimethoprim/sulfamethoxazole for Pneumocystis, and acyclovir (Zovirax) for varicella zoster. They also considered combinations of pentostatin with agents such as interferon, rituximab (Rituxan), and chlorambucil (Leukeran) and their effect on the immune system. The biology of B and T cells was discussed, with an emphasis on clinical application.

AB - Managing the infectious complications associated with pentostatin (Nipent), used alone or in combination with other agents in patients with low-grade lymphomas, poses a significant problem for clinicians. Since there is limited experience with these therapies, definitive treatment recommendations concerning prophylaxis cannot be made. The panel members discussed the use of valacyclovir (Valtrex) to provide prophylaxis for herpes zoster, trimethoprim/sulfamethoxazole for Pneumocystis, and acyclovir (Zovirax) for varicella zoster. They also considered combinations of pentostatin with agents such as interferon, rituximab (Rituxan), and chlorambucil (Leukeran) and their effect on the immune system. The biology of B and T cells was discussed, with an emphasis on clinical application.

UR - http://www.scopus.com/inward/record.url?scp=0034199060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034199060&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 41

EP - 42

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 6 Suppl 2

ER -